Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 2/3 1Phase 1 1

Status

Completed 5Recruiting 2

Sponsor Class

OTHER 7INDUSTRY 3

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Gastrointestinal 142Sarcoma 22Tumor-Agnostic 8CNS 7Thoracic 5Gynecologic 5Other solid neoplasm 4Other hematologic neoplasm 4Genitourinary 4Dermatologic 4Plasma cell 2Myeloid 2Lymphoid 2Head & Neck 2Endocrine 2Breast 2NET 1Classical hematology 1

Conditions

Glioblastoma 5Recurrence 1Meningioma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Temozolomide 400Radiotherapy 239Bevacizumab 185Magnetic Resonance Spectroscopy 168Radiosurgery 142Cyclophosphamide 95Irinotecan 79Carboplatin 79Etoposide 78Radiation 76pembrolizumab 70Nivolumab 59Surgical Procedures, Operative 57Filgrastim 56Specimen Handling 53Cisplatin 50Blood Specimen Collection 46Topotecan 45Vincristine 43Melphalan 38Radiotherapy, Intensity-Modulated 36Pemetrexed 36Lomustine 36Ipilimumab 36Everolimus 35Magnetic Resonance Imaging 34Erlotinib Hydrochloride 34Drug Therapy 34Surveys and Questionnaires 33sargramostim 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
OTHER × regorafenib × CNS × Clear all
NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT06275919 2026-05-13

MIRAGE

Istituto Oncologico Veneto IRCCS

Phase 2 Recruiting
104 enrolled
CNS

Meningioma

NCT06095375 2026-01-09

REGOMA-2

Istituto Oncologico Veneto IRCCS

Phase 1 Completed
21 enrolled
CNS

Glioblastoma

NCT04051606 2025-06-05

Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma

Case Comprehensive Cancer Center

Phase 2 Completed
14 enrolled
CNS

Glioblastoma

NCT04810182 2024-02-08

Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS

Istituto Oncologico Veneto IRCCS

Completed
192 enrolled
CNS

Glioblastoma

NCT03520842 2023-08-01

Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer

Stanford University

Phase 2 Completed
22 enrolled 20 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02926222 2022-09-09

REGOMA

Istituto Oncologico Veneto IRCCS

Phase 2 Completed
119 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡